CLINICAL EFFICACY OF CEFTAZIDIME/AVIBACTAM VERSUS OTHER ACTIVE AGENTS FOR THE TREATMENT OF BACTEREMIA DUE TO CARBAPENEMASE-PRODUCING ENTEROBACTERIACEAE IN HEMATOLOGIC PATIENTS

Highlights • The majority of CPE corresponded to OXA-48 isolations. • CPE bacteremia is associated with high mortality in hematologic patients. • Mortality was associated with septic shock and higher Pitt score. • Therapy with ceftazidime/avibactam was not associated with increased survival. • Patie...

Full description

Saved in:
Bibliographic Details
Published in:International journal of infectious diseases 2017-06, Vol.59 (C), p.118-123
Main Authors: Castón, Juan J, Lacort, Isabel, Martín-Dávila, Pilar, Loeches, Belén, Tabares, Salvador, Temkin, Liz, Torre-Cisneros, Julián, Paño, José R
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
Azabicyclo Compounds - therapeutic use
Bacteremia - complications
Bacteremia - drug therapy
Bacteremia - microbiology
Bacterial Proteins - biosynthesis
beta-Lactamases - biosynthesis
Bloodstream infections
Carbapenemase-producing Enterobacteriaceae
Ceftazidime - therapeutic use
Ceftazidime-avibactam
Cohort Studies
Drug Therapy, Combination
Enterobacteriaceae - enzymology
Enterobacteriaceae Infections - drug therapy
Female
Hematologic Neoplasms - complications
Humans
Infectious Disease
Male
Microbial Sensitivity Tests
Middle Aged
Pulmonary/Respiratory
Retrospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • The majority of CPE corresponded to OXA-48 isolations. • CPE bacteremia is associated with high mortality in hematologic patients. • Mortality was associated with septic shock and higher Pitt score. • Therapy with ceftazidime/avibactam was not associated with increased survival. • Patients who received ceftazidime/avibactam had higher clinical cure rates
ISSN:1201-9712
1878-3511
DOI:10.1016/j.ijid.2017.03.021